MACKENZIE FINANCIAL CORP - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 188 filers reported holding DENALI THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 2.00 and the average weighting 0.2%.

Quarter-by-quarter ownership
MACKENZIE FINANCIAL CORP ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$310,601
+40.3%
10,465
+31.5%
0.00%
Q4 2022$221,340
+10.7%
7,959
+22.1%
0.00%
Q3 2022$200,000
-1.5%
6,521
-5.5%
0.00%
Q2 2022$203,000
-37.9%
6,898
-5.9%
0.00%
Q4 2021$327,000
-13.3%
7,331
-1.9%
0.00%
-100.0%
Q3 2021$377,000
+22.4%
7,474
+90.4%
0.00%
Q2 2021$308,0003,9250.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$219,569,00028.65%
ARCH Venture Management, LLC 5,168,749$152,116,00018.54%
Casdin Capital, LLC 1,500,000$44,145,0003.73%
Flagship Pioneering Inc. 2,619,968$77,106,0002.90%
Yiheng Capital Management, L.P. 1,014,684$29,862,0001.71%
SECTORAL ASSET MANAGEMENT INC 202,100$5,948,0001.20%
GILDER GAGNON HOWE & CO LLC 1,956,820$57,589,0001.03%
Artal Group S.A. 600,000$17,658,0000.94%
Temasek Holdings (Private) Ltd 5,369,487$158,024,0020.87%
BRANDYWINE MANAGERS, LLC 9,601$283,0000.69%
View complete list of DENALI THERAPEUTICS INC shareholders